Cargando…
Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries
IMPORTANCE: Vaccinations are paramount to halt the COVID-19 pandemic, and safety data are essential to determine the risk-benefit ratio of each COVID-19 vaccine. OBJECTIVE: To evaluate the association between the AZD1222, BNT162b2, and mRNA-1273 vaccines and subsequent thromboembolic and thrombocyto...
Autores principales: | Dag Berild, Jacob, Bergstad Larsen, Vilde, Myrup Thiesson, Emilia, Lehtonen, Toni, Grøsland, Mari, Helgeland, Jon, Wolhlfahrt, Jan, Vinsløv Hansen, Jørgen, Palmu, Arto A., Hviid, Anders |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198750/ https://www.ncbi.nlm.nih.gov/pubmed/35699955 http://dx.doi.org/10.1001/jamanetworkopen.2022.17375 |
Ejemplares similares
-
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study
por: Andersson, Niklas Worm, et al.
Publicado: (2022) -
Azd-1222: Immune thrombocytopenic purpura: case report
Publicado: (2021) -
Azd-1222: Thrombotic thrombocytopenic purpura: case report
Publicado: (2021) -
AZD-1222: Immune thrombocytopenic purpura: case report
Publicado: (2021) -
Azd-1222: Thrombotic thrombocytopenic purpura: case report
Publicado: (2022)